

Please complete this **entire** form and fax it to: **866-940-7328**. If you have questions, please call **800-310-6826**.
This form contains multiple pages. Please complete all pages to avoid a delay in our decision.
Allow at least 24 hours for review.

Section A – Member Information

First Name:	Last Name:	Member ID:
Address:		
City:	State:	ZIP Code:
Phone:	DOB:	Allergies:
Primary Insurance:	Policy #:	Group #:

Is the requested medication New or Continuation of Therapy? If continuation, list start date: _____
 Is this patient currently hospitalized? Yes No If recently discharged, list discharge date: _____

Section B - Physician Information

First Name:	Last Name:			M.D./D.O.
Address:		City:	State:	ZIP code:
Phone:	Fax:	NPI #:	Specialty:	
Office Contact Name / Fax attention to:				

Section C - Medical Information

Medication:	Strength:
Directions for use:	Quantity:
Diagnosis (Please be specific & provide as much information as possible):	ICD-10 CODE:
Is this member pregnant? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, what is this member's due date? _____	

Section D – Previous Medication Trials

Medications	Strength	Directions	Dates of Therapy	Reason for failure / discontinuation

Section E – Additional information and Explanation of why preferred medications would not meet the patient's needs
Please refer to www.uhccommunityplan.com for a list of preferred alternatives

Member First name:	Member Last name:	Member DOB:
Clinical and Drug Specific Information		
ALL REQUESTS		
<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the patient have any of the following diagnoses? <i>(If yes, check which applies)</i> <input type="checkbox"/> Moderately to severely active rheumatoid arthritis (RA) <input type="checkbox"/> Moderately to severely active polyarticular juvenile idiopathic arthritis <input type="checkbox"/> Active psoriatic arthritis <input type="checkbox"/> Moderate to severe chronic plaque psoriasis <input type="checkbox"/> Ankylosing spondylitis	
<input type="checkbox"/> Yes <input type="checkbox"/> No	Is Enbrel prescribed or recommended by one of the following? <i>(If yes, check which applies)</i> <input type="checkbox"/> Dermatologist <input type="checkbox"/> Rheumatologist	
<input type="checkbox"/> Yes <input type="checkbox"/> No	Is the patient receiving Enbrel in combination with any of the following? <i>(If yes, check which applies)</i> <input type="checkbox"/> Biologic DMARD [e.g. Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab)] <input type="checkbox"/> Janus Kinase inhibitor [e.g. Xeljanz (tofacitinib)] <input type="checkbox"/> Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]	
RHEUMATOID ARTHRITIS		
<input type="checkbox"/> Yes <input type="checkbox"/> No	Is there a history of failure, contraindication, or intolerance to any non-biologic disease modifying anti-rheumatic drug (DMARD) [e.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine]? <i>(If yes, complete Section D above)</i>	
JUVENILE IDIOPATHIC ARTHRITIS		
<input type="checkbox"/> Yes <input type="checkbox"/> No	Is there a history of failure, contraindication, or intolerance to any of the following DMARDs? <i>(If yes, check which applies and complete Section D above)</i> <input type="checkbox"/> Leflunomide (Arava) <input type="checkbox"/> Methotrexate (Rheumatrex/Trexall)	
ANKYLOSING SPONDYLITIS		
<input type="checkbox"/> Yes <input type="checkbox"/> No	Is there a history of failure, contraindication, or intolerance to two or more NSAIDs? <i>(If yes, complete Section D above)</i>	
CONTINUATION OF THERAPY		
<input type="checkbox"/> Yes <input type="checkbox"/> No	Is there documentation of positive clinical response to Enbrel therapy? <i>If yes, list response:</i>	

Physician Signature: _____ **Date:** _____

Confidentiality Notice: This transmission contains confidential information belonging to the sender and United HealthCare. This information is intended only for the use of United HealthCare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately. Website: uhccommunityplan.com